Why the study?
Targeting ANGPTL3, ANGPTL4, and ANGPTL8 may provide new therapeutic avenues for metabolic and cardiovascular disease through their role as principal regulators of plasma lipid metabolism.
Design
Systematic review
Authors
Loading...
May support ANGPTL3-4-8 as lipid targets; leaves open clinical efficacy and safety in CVD.
Targeting the ANGPTL3-4-8 triad with monoclonal antibodies or antisense oligonucleotides offers a potential future strategy for treating hypertriglyceridemia and reducing cardiovascular risk.
Morelli et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: